Skip to main content
SpringerLink
Log in

Biological Approaches to the Therapy of Pancreatic Cancer

  • Chapter
Book cover Pancreatic Disease

  • 82 Accesses

Abstract

Treatment of adenocarcinoma of the pancreas remains a challenging task. Some improvements have occurred in surgical management. Although a relatively small proportion of patients who present with pancreatic adenocarcinoma are candidates for surgery, it is now clear that in experienced centers, the perioperative mortality can be less than 5% [1]. Furthermore, the addition of adjuvant 5-fluorouracil (5-FU)-based chemoradiation may have a role in prolonging the median survival following surgery [2]. Despite these advances, the 5-year survival for pancreatic adenocarcinoma in the United States has improved only slightly and remains low at 4% [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Crist DW, Cameron JL (1994) The current status of the Whipple operation for periampullary carcinoma. Adv Surg 25:21–49

    Google Scholar 

  2. Kaiser MH, Ellenberg SS (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903

    Google Scholar 

  3. Landis SH, Murray T, Bolden S, Bolden S, Wingo PA (1998) Cancer Statistics, 1998. CA Cancer J Clin 48:6–29

    Article  PubMed  CAS  Google Scholar 

  4. Moertel CG, Frytak S, Hahn RG, et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high-dose (6000 rads) radiation alone, moderate-dose radiation (4000 rads+5-fluorouracil), and high-dose radiation+5-fluorouracil. Cancer 48:1705–1710

    Article  PubMed  CAS  Google Scholar 

  5. Burris HA, Moore MJ, Andersen J, et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  6. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654–663

    PubMed  CAS  Google Scholar 

  7. Keating JJ, Johnson PJ, Cochrane AMG, et al (1989) A prospective randomised trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60:789–792

    Article  PubMed  CAS  Google Scholar 

  8. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, Harris AL (1993) Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist groserelin plus hydrocortisone. Br J Cancer 67:379–382

    Article  PubMed  CAS  Google Scholar 

  9. Glimelius B, Hoffman K, Sjödén PO, et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    PubMed  CAS  Google Scholar 

  10. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard CF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885

    Article  PubMed  CAS  Google Scholar 

  11. Mallinson CN, Rake MO, Cocking JD (1980) Chemotherapy in pancreatic cancer. Br Med J 281:1589–1591

    Article  PubMed  CAS  Google Scholar 

  12. Frey C, Twomey P, Keehn R, Elliott D, Higgins G (1981) Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 47:27–31

    Article  PubMed  CAS  Google Scholar 

  13. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554

    Article  Google Scholar 

  14. Hruban RH, van Mansfeld ADM, Offerhaus GJA, et al (1989) K-ras oncogene activation in adenocarcinomas of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545–554

    Google Scholar 

  15. Ito T, Kawata S, Tamura S, et al (1996) Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl protein transferase inhibitor. Jpn J Can Res 87:113–116

    CAS  Google Scholar 

  16. Gibbs JB, Kohl NE, Koblan KS, et al (1996) Farnesyl transferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat 38:75–83

    Article  PubMed  CAS  Google Scholar 

  17. Hohl RJ, Lewis K (1995) Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270:17508–17512

    Article  PubMed  CAS  Google Scholar 

  18. Stark MJ, Burke YD, McKinzie JH, et al (1995) Chemotherapy of pancreatic cancer with monoterpene perillyl alcohol. Cancer Lett 96:15–21

    Article  PubMed  CAS  Google Scholar 

  19. Ripple G, Gould M, Arzoomanian R, et al (1998) Phase I trial of perillyl alcohol administered four times a day. ASCO Proc 17:231a, Abstr 885

    Google Scholar 

  20. Liotta LA, Tryggvason K, Garbisa S, et al (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67–68

    Article  PubMed  CAS  Google Scholar 

  21. Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:5054–5059

    Google Scholar 

  22. Bramhall S (1997) The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 21:1–12

    PubMed  CAS  Google Scholar 

  23. Shichinohe T, Senmaru N, Furuuchi K, et al (1996) Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 66:125–130

    Article  PubMed  CAS  Google Scholar 

  24. Moelling K, Strack B, Radziwill G (1996) Signal transduction as target of gene therapy. Rec Res Cancer Res 142:63–71

    CAS  Google Scholar 

  25. Clayman GL, el Naggar AK, Roth JA, et al (1995) In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1–6

    PubMed  CAS  Google Scholar 

  26. Bischoff JR, Kirn DH, Williams A (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376

    Article  PubMed  CAS  Google Scholar 

  27. Mulvihill SJ, Warren RS, Fell S, et al (1998) A phase I trial of intratumoral injection with an E IB-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas. ASCO Proc 17:211a, Abstr 815

    Google Scholar 

  28. Joshi US, Dergham ST, Chen YQ, et al (1998) Inhibition of pancreatic tumor cell growth in culture by p21WAFl recombinant adenovirus. Pancreas 16:107–113

    Article  PubMed  CAS  Google Scholar 

  29. Barton CM, Lemoine NR (1995) Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 71:429–437

    Article  PubMed  CAS  Google Scholar 

  30. Aoki K, Yoshida T, Matsumoto N, et al (1997) Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 8:1105–1113

    Article  PubMed  CAS  Google Scholar 

  31. Ohashi M, Kanai F, Tanaka T, et al (1998) In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 89:457–462

    PubMed  CAS  Google Scholar 

  32. Evoy D, Hirschowitz EA, Naama HA, et al (1997) In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 69:226–231

    Article  PubMed  CAS  Google Scholar 

  33. Green NK, Youngs DJ, Neoptolemos JP, et al (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 4:229–238

    PubMed  CAS  Google Scholar 

  34. Thor A, Ohuchi N, Szpak CA, Johnson WW, Schlom J (1986) The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118–3124

    PubMed  CAS  Google Scholar 

  35. Buchsbaum DJ, Lawrence TS, Roberson PL, et al (1993) Comparison of 131I-and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int J Radiat Oncol Biol Phys 25:629–638

    Article  PubMed  CAS  Google Scholar 

  36. Juweid M, Sharkey RM, Swayne LC, Griffith GL, Dunn R, Goldenberg DM (1998) Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 39:34–42

    PubMed  CAS  Google Scholar 

  37. Welt S, Scott AM, Divgi CR, et al (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14:1787–1797

    PubMed  CAS  Google Scholar 

  38. Alisauskus R, Wong GY, Gold DV (1995) Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res 55:5743–5748

    Google Scholar 

  39. Molinolo A, Simpsom JF, Thor A, Schlom J (1990) Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50:1291–1298

    PubMed  CAS  Google Scholar 

  40. Tempero MA, Leichner P, Dalrymple G, et al (1997) High dose therapy with 131I labeled monoclonal antibody CC49: a phase I trial. J Clin Oncol 15:1518–1528

    PubMed  CAS  Google Scholar 

  41. Leichner PK, Akabani G, Colcher D, et al (1997) Patient-specific dosimetry of indium-111/yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38:512–516

    PubMed  CAS  Google Scholar 

  42. Kashmiri SVS, Shu L, Padlan EA, et al (1995) Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14:461–473

    Article  PubMed  CAS  Google Scholar 

  43. Beresford GW, Pavlinkova G, Booth BJM, Batra SK, Colcher D (1998) Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody

    Google Scholar 

  44. Okazaki S, Tempero MA, Colcher D (1998) Combination radioimmunotherapy and chemotherapy using 131I-B72.3 and gemcitabine. AACR Proc 39:310, Abstr 2119

    Google Scholar 

  45. Marani G, Molea N, Bacciardi D, et al (1995) Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res 55:5911–5915

    Google Scholar 

  46. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856–2860

    PubMed  CAS  Google Scholar 

  47. Karanikas V, Hwang LA, Pearson J, et al (1997) Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC2 fusion protein. J Clin Invest 100:2783–2792

    Article  PubMed  CAS  Google Scholar 

  48. Gjertsen MJ, Bakka A, Breivik J, et al (1996) Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 65:450–453

    Article  PubMed  CAS  Google Scholar 

  49. Reddish MA, MacLean GD, Poppema S, Berg A, Longnecker BM (1996) Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 42:303–309

    Article  PubMed  CAS  Google Scholar 

  50. Clary BM, Coveney EC, Philip R, et al (1997) Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther 4:97–104

    PubMed  CAS  Google Scholar 

  51. Jaffee EM, Pardoll DM (1997) Considerations for the clinical development of cytokine gene-transducted tumor cell vaccines. Methods 12:143–153

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. A. Tempero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Tempero, M.A. (1999). Biological Approaches to the Therapy of Pancreatic Cancer. In: Pancreatic Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60068-5_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60068-5_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-65357-8

  • Online ISBN: 978-3-642-60068-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation